7,448.75

+46.75

+0.63%

51,882.00

+497.00

+0.97%

27,237.50

+152.25

+0.56%

Russell 2000 Futures

2,796.30

+35.80

+1.30%

4.8590

+0.0220

+0.45%

23.59

-2.05

-7.99%

4,123.80

+48.90

+1.20%

74,804.16

-1,064.16

-1.40%

Crude Oil Dec 26

88.25

-2.58

-2.84%

US Private Equity

10,772.76

+11.83

+0.11%

NYSE American - Delayed Quote USD

Calidi Biotherapeutics, Inc. (CLDI)

0.7001 +0.0211 (+3.11%)

At close: November 6 at 3:19:24 PM EST

0.7690 +0.0689 (+9.84%)

Pre-Market: 6:09:48 AM EST

Loading Chart for CLDI

Chart Range Bar

Interval:

In partnership with ChartIQ

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

Mobilize your Website

View Site in Mobile | Classic

Share by: